Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Abstract Background Anti-HIV-1 broadly neutralizing antibodies (bnAbs) have been developed as potential agents for prevention of HIV-1 infection. The HIV Vaccine Trials Network and the HIV Prevention Trials Network are conducting the Antibody Mediated Prevention (AMP) trials to assess whether, and how, intravenous infusion of the anti-CD4 binding site bnAb, VRC01, prevents HIV-1 infection. These are the first test-of-concept studies to assess HIV-1 bnAb prevention efficacy in humans. Methods The AMP trials are two parallel phase 2b HIV-1 prevention efficacy trials conducted in two cohorts: 2700 HIV-uninfected men and transgender persons who have sex with men in the United States, Peru, Brazil, and Switzerland; and 1500 HIV-uninfected sexually active women in seven countries in sub-Saharan Africa. Participants are randomized 1:1:1 to receive an intravenous infusion of 10 mg/kg VRC01, 30 mg/kg VRC01, or a control preparation every 8 weeks for a total of 10 infusions. Each trial is designed (1) to assess overall prevention efficacy (PE) pooled over the two VRC01 dose groups vs. control and (2) to assess VRC01 dose and laboratory markers as correlates of protection (CoPs) against overall and genotype- and phenotype-specific infection. Results Each AMP trial is designed to have 90 % power to detect PE > 0 % if PE is ≥ 60 %. The AMP trials are also designed to identify VRC01 properties (i. e., concentration and effector functions) that correlate with protection and to provide insight into mechanistic CoPs. CoPs are assessed using data from breakthrough HIV-1 infections, including genetic sequences and sensitivities to VRC01-mediated neutralization and Fc effector functions. Conclusions The AMP trials test whether VRC01 can prevent HIV-1 infection in two study populations. If affirmative, they will provide information for estimating the optimal dosage of VRC01 (or subsequent derivatives) and identify threshold levels of neutralization and Fc effector functions associated with high-level protection, setting a benchmark for future vaccine evaluation and constituting a bridge to other bnAb approaches for HIV-1 prevention.

[1]  P. Gilbert,et al.  Power/sample size calculations for assessing correlates of risk in clinical efficacy trials , 2016, Statistics in medicine.

[2]  J. Gallant,et al.  Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.

[3]  M. Hudgens,et al.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. , 2016, The Journal of infectious diseases.

[4]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[5]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[6]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[7]  J. Mascola,et al.  Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults , 2015, Clinical and experimental immunology.

[8]  B. Graham,et al.  History of passive antibody administration for prevention and treatment of infectious diseases , 2015, Current opinion in HIV and AIDS.

[9]  Youyi Fong,et al.  Change point testing in logistic regression models with interaction term , 2015, Statistics in medicine.

[10]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[11]  James Y. Dai,et al.  Tenofovir-based preexposure prophylaxis for HIV infection among African women. , 2015, The New England journal of medicine.

[12]  P. Gilbert,et al.  Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. , 2014, The Journal of infectious diseases.

[13]  J. Mascola,et al.  Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.

[14]  A. Fauci,et al.  Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Mascola,et al.  Enhanced neonatal Fc receptor function improves protection against primate SHIV infection , 2014, Nature.

[16]  J. Hoxie,et al.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.

[17]  J. Kublin,et al.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. , 2014, The Lancet. Infectious diseases.

[18]  D. Montefiori Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy , 2014, Human vaccines & immunotherapeutics.

[19]  P. Gilbert,et al.  Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy. , 2014, Biostatistics.

[20]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[21]  S. Hammer,et al.  In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. , 2013, AIDS research and human retroviruses.

[22]  I. Georgiev,et al.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. , 2013, Current opinion in HIV and AIDS.

[23]  S. Buchbinder,et al.  Correlates of HIV Acquisition in a Cohort of Black Men Who Have Sex with Men in the United States: HIV Prevention Trials Network (HPTN) 061 , 2013, PloS one.

[24]  J. Wolfson,et al.  Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials , 2013, Biometrics.

[25]  Yan Liu,et al.  Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 , 2013, Nature Structural &Molecular Biology.

[26]  M. Friend,et al.  Diagnoses of HIV infection in the United States and dependent areas, 2016 , 2013 .

[27]  D. Burton,et al.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.

[28]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[29]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[30]  Douglas J. Taylor,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[31]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[32]  P. Gilbert,et al.  Nomenclature for immune correlates of protection after vaccination. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  L. van Damme,et al.  Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention , 2012, AIDS.

[34]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[35]  Tongqing Zhou,et al.  PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4 , 2012, Journal of Virology.

[36]  Myron S. Cohen,et al.  Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission , 2011, Science Translational Medicine.

[37]  Young Do Kwon,et al.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.

[38]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[39]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[40]  Lei Wang,et al.  Prevention of HIV-1 infection with early antiretroviral therapy. , 2011, The New England journal of medicine.

[41]  J. Kublin,et al.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.

[42]  M. J. Laan,et al.  Targeted Learning: Causal Inference for Observational and Experimental Data , 2011 .

[43]  J. Mascola,et al.  Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses , 2011, Journal of Virology.

[44]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[45]  Peter B Gilbert,et al.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens , 2011, Statistical communications in infectious diseases.

[46]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[47]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[48]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[49]  Allan C. deCamp,et al.  Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. , 2010, The Journal of infectious diseases.

[50]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[51]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[52]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[53]  D. Burton,et al.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.

[54]  Peter B Gilbert,et al.  Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts , 2010, Statistics in medicine.

[55]  R. Gray,et al.  A general inefficacy interim monitoring rule for randomized clinical trials , 2010, Clinical trials.

[56]  Q. Sattentau,et al.  Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.

[57]  World Medical Association (WMA),et al.  Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.

[58]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[59]  Lynn Morris,et al.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.

[60]  L. Lopalco,et al.  HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis , 2009, Mucosal Immunology.

[61]  Lynn Morris,et al.  Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.

[62]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[63]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[64]  D. Venzon,et al.  Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines1 , 2009, The Journal of Immunology.

[65]  S. Self,et al.  Simultaneous Evaluation of the Magnitude and Breadth of a Left- and Right-Censored Multivariate Response, With Application to HIV Vaccine Development , 2009, Statistics in biopharmaceutical research.

[66]  Michael G Hudgens,et al.  Evaluating Candidate Principal Surrogate Endpoints , 2008, Biometrics.

[67]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[68]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[69]  Lisa M. Lee,et al.  Estimation of HIV incidence in the United States. , 2008, JAMA.

[70]  Scott Rose,et al.  Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[71]  Peter B Gilbert,et al.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. , 2008, The annals of applied statistics.

[72]  Mark Connors,et al.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.

[73]  N. Jewell,et al.  Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial , 2007, The Lancet.

[74]  Dean Follmann,et al.  Augmented Designs to Assess Immune Response in Vaccine Trials , 2006, Biometrics.

[75]  M. Gottlieb,et al.  Pneumocystis pneumonia--Los Angeles. , 2006, MMWR. Morbidity and mortality weekly report.

[76]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[77]  P. Gilbert,et al.  Accuracy and precision of estimating intervention efficacy when the timing of observed events differ by treatment arm. , 2005, Contemporary clinical trials.

[78]  G. Landucci,et al.  Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[79]  Thomas R Fleming,et al.  Some design issues in trials of microbicides for the prevention of HIV infection. , 2004, The Journal of infectious diseases.

[80]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[81]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[82]  Patricia M. Grambsch,et al.  Data Monitoring Committees in Clinical Trials: A Practical Perspective. , 2003 .

[83]  H. Katinger,et al.  Postnatal pre‐ and postexposure passive immunization strategies: protection of neonatal macaques against oral simian–human immunodeficiency virus challenge , 2002, Journal of medical primatology.

[84]  N. Haigwood,et al.  Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.

[85]  E. Emanuel,et al.  The ethics of placebo-controlled trials--a middle ground. , 2001, The New England journal of medicine.

[86]  C. Grady,et al.  What makes clinical research ethical? , 2000, JAMA.

[87]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[88]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[89]  T. Fleming,et al.  Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[90]  T. D. Schneider,et al.  Sequence logos: a new way to display consensus sequences. , 1990, Nucleic acids research.

[91]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[92]  Mark J. van der Laan,et al.  Application of Time-to-Event Methods in the Assessment of Safety in Clinical Trials , 2009 .

[93]  J. Prejean,et al.  Estimated HIV Incidence in the United States, 2006–2009 , 2011, PloS one.